1921
Volume 98, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Laboratory data and prior pediatric reports indicate that HIV protease inhibitor (PI)–based antiretroviral therapy (ARV) kills gametocytes and reduces rates of gametocytemia, but not asymptomatic parasitemia, in a high malaria-transmission area. To determine whether ARV regimen impacts these rates in areas with less-intense malaria transmission, we compared asymptomatic parasitemia and gametocytemia rates in HIV-infected children by ARV regimen in Lilongwe, Malawi, an area of low-to-moderate transmission intensity. HIV PI lopinavir–ritonavir (LPV–rtv) ARV– or non-nucleoside reverse transcriptase inhibitor nevirapine ARV–treated children did not differ in the rates of polymerase chain reaction-detected asymptomatic parasitemia (relative risk [RR] 0.43 95% confidence interval [CI] [0.16, 1.18], value 0.10) or microscopically detected gametocytemia with LPV–rtv ARV during symptomatic malaria (RR 0.48 95% CI [0.22,1.04] value 0.06). LPV–rtv ARV was not associated with reduced rates of asymptomatic parasitemia, or gametocytemia on days of symptomatic malaria episodes, in HIV-infected children. Larger studies should evaluate whether ARV impacts transmission.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.17-0462
2018-01-10
2018-04-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/98/1/tpmd170462.html?itemId=/content/journals/10.4269/ajtmh.17-0462&mimeType=html&fmt=ahah

References

  1. Flateau C, Le Loup G, Pialoux G, , 2011. Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 11: 541556.
  2. Hobbs CV, De La Vega P, Penzak SR, Van Vliet J, Krzych U, Sinnis P, Borkowsky W, Duffy PE, , 2013. The effect of antiretrovirals on Plasmodium falciparum liver stages. AIDS 27: 16741677.
  3. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ, , 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 49: 29832985.
  4. Hobbs CV, Tanaka TQ, Muratova O, Van Vliet J, Borkowsky W, Williamson KC, Duffy PE, , 2013. HIV treatments have malaria gametocyte killing and transmission blocking activity. J Infect Dis 208: 139148.
  5. Peatey CL, Andrews KT, Eickel N, MacDonald T, Butterworth AS, Trenholme KR, Gardiner DL, McCarthy JS, Skinner-Adams TS, , 2010. Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors. Antimicrob Agents Chemother 54: 13341337.
  6. Skinner-Adams TS, McCarthy JS, Gardiner DL, Hilton PM, Andrews KT, , 2004. Antiretrovirals as antimalarial agents. J Infect Dis 190: 19982000.
  7. WHO, 2015. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: What’s New. Available at: http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/. Accessed March 4, 2016.
  8. Hobbs CV, Parikh S, , 2017. Buy one, get one free? Benefits of certain antiretrovirals against malaria. AIDS 31: 583585.
  9. Achan J, 2012. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 367: 21102118.
  10. Hobbs CV, 2016. Malaria in HIV-infected children receiving HIV protease-inhibitor- compared with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy, IMPAACT P1068s, substudy to P1060. PLoS One 11: e0165140.
  11. Parikh S, 2016. Antiretroviral choice for HIV impacts antimalarial exposure and treatment outcomes in Ugandan children. Clin Infect Dis 63: 414422.
  12. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT, , 2009. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51: 424429.
  13. Ikilezi G, Achan J, Kakuru A, Ruel T, Charlebois E, Clark TD, Rosenthal PJ, Havlir D, Kamya MR, Dorsey G, , 2013. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg. 88: 744746.
  14. Violari A, 2012. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 366: 23802389.
  15. WHO, 2015. Guidelines for the Treatment of Malaria – 3rd edition. Available at: http://www.who.int/malaria/publications/atoz/9789241549127/en/.
  16. WHO. 2006–2011 Documents. Integrated Management of Childhood Illness. Available at: http://www.who.int/maternal_child_adolescent/documents/imci/en/. Accessed April 23, 2015.
  17. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP, , 1999. Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119: 113125.
  18. Shaukat AM, 2012. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malar J 11: 207.
  19. Lindblade KA, Steinhardt L, Samuels A, Kachur SP, Slutsker L, , 2013. The silent threat: asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect Ther 11: 623639.
  20. Bousema T, Drakeley C, , 2011. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24: 377410.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.17-0462
Loading
/content/journals/10.4269/ajtmh.17-0462
Loading

Data & Media loading...

  • Received : 13 Jun 2017
  • Accepted : 13 Sep 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error